Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into bluebird bio, Inc. (NasdaqGS: BLUE).
In May 2020, the Company announced its plans to submit an application to the U.S. Food and Drug Administration (“FDA”) for its product, LentiGlobin, in the second half of 2021. Then, on November 4, 2020, the Company disclosed that, due to the FDA requiring the Company to provide additional data, it was adjusting the timing of its submission to late 2022.
Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period in violation of federal securities laws, which remains ongoing.
KSF’s investigation is focusing on whether bluebird’s officers and/or directors breached their fiduciary duties to bluebird’s shareholders or otherwise violated state or federal laws.
If you have information that would assist KSF in its investigation, or have been a long-term holder of bluebird shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (firstname.lastname@example.org), or fill out the form on this page.